Calviv® (Tablets) Instructions for Use
ATC Code
A12AA20 (Combination of various calcium salts)
Active Substances
Calcium carbonate (Ph.Eur.)
Calcium lactate gluconate (BP)
Clinical-Pharmacological Group
Drug replenishing calcium deficiency in the body
Pharmacotherapeutic Group
Calcium-phosphorus metabolism regulator
Pharmacological Action
A means for replenishing calcium deficiency in the body, contains two calcium salts – Calcium carbonate and Calcium lactate gluconate.
Calcium is a vital mineral element necessary for maintaining electrolyte balance in the body and the adequate functioning of numerous regulatory mechanisms.
It participates in phosphate-calcium metabolism and has vitamin, anti-rachitic, anti-inflammatory, and anti-allergic effects.
Pharmacokinetics
Approximately 25-50% of the orally administered dose of calcium is absorbed, mainly in the proximal part of the small intestine, and enters the metabolic calcium depots.
99% of the body’s calcium stores are contained in bones and teeth, 1% is found in the composition of intra- and extracellular fluid.
Approximately 50% of the total calcium content in the blood is present in the physiologically active ionized form, approximately 5% forms complexes with citrate, phosphate, and other anions.
The remaining 45% of calcium in the blood serum is bound to proteins, mainly albumin.
About 20% of calcium is excreted through the kidneys and 80% through the intestines.
The level of renal excretion depends on glomerular filtration and tubular reabsorption.
Both non-absorbed calcium and that absorbed portion which is secreted with bile and pancreatic secretion are excreted through the intestines.
Indications
Prevention and treatment of calcium deficiency (including pregnancy, lactation period, period of intensive growth in children); addition of calcium to specific therapy for the prevention and treatment of osteoporosis; allergic reactions (supportive therapy); osteomalacia (as an addition to the main therapy, including with vitamin D3).
ICD codes
| ICD-10 code | Indication |
| E58 | Dietary calcium deficiency |
| M80.0 | Postmenopausal osteoporosis with pathological fracture |
| M80.1 | Osteoporosis with pathological fracture following oophorectomy |
| M80.2 | Osteoporosis with pathological fracture, caused by immobilization |
| M80.4 | Drug-induced osteoporosis with pathological fracture |
| M80.5 | Idiopathic osteoporosis with pathological fracture |
| M80.8 | Other osteoporosis with pathological fracture |
| M81.0 | Postmenopausal osteoporosis |
| M81.1 | Postoophorectomy osteoporosis |
| M81.2 | Osteoporosis due to immobilization |
| M81.4 | Drug-induced osteoporosis |
| M81.5 | Idiopathic osteoporosis |
| M81.8 | Other osteoporosis (senile osteoporosis) |
| M82 | Osteoporosis in diseases classified elsewhere |
| M83 | Adult osteomalacia |
| O25 | Nutritional deficiencies in pregnancy |
| T78.4 | Allergy, unspecified |
| Z39.1 | Care and examination of lactating mother |
| ICD-11 code | Indication |
| 4A8Z | Allergic conditions or hypersensitivity conditions of unspecified type |
| 5B5K.1Z | Calcium deficiency, unspecified |
| 8D40.2 | Myopathy due to nutritional deficiency |
| FB83.10 | Premenopausal idiopathic osteoporosis |
| FB83.11 | Postmenopausal osteoporosis |
| FB83.12 | Osteoporosis due to disuse |
| FB83.13 | Drug-induced osteoporosis |
| FB83.1Z | Osteoporosis, unspecified |
| FB83.2Z | Adult osteomalacia, unspecified |
| JA64 | Nutritional disorders during pregnancy |
| QA48.1 | Care or examination of a nursing mother |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally. Ingestion is independent of meals. Chew or swallow the tablet whole with a full glass of water.
For adults and adolescents over 12 years, the typical dose is 1-2 tablets, taken two to three times daily.
For children aged 3 to 12 years, the typical dose is 1 tablet, taken one to two times daily.
Adjust the total daily dose and duration of therapy based on the clinical indication, severity of calcium deficiency, and individual patient requirements.
Do not exceed the maximum recommended daily intake of 1500 mg of elemental calcium from all sources without specific medical instruction.
For pregnant and lactating women, adhere strictly to the dose prescribed by a physician. The daily dose during pregnancy must not exceed 1500 mg.
In patients with mild to moderate renal impairment or a history of urolithiasis, initiate therapy only under medical supervision. Monitor urinary calcium excretion regularly.
For optimal absorption, maintain an interval of at least 2 hours before or 4-6 hours after taking tetracycline or quinolone antibiotics.
Maintain an interval of at least 3 hours before taking oral bisphosphonates or sodium fluoride.
Avoid concurrent intake with food high in oxalic acid (spinach, rhubarb) or phytic acid (whole grains). Take the tablet 2 hours before or after such meals.
Adverse Reactions
Very rarely hypersensitivity reactions, including rash, itching, urticaria, hypercalcemia. In isolated cases, systemic allergic reactions (anaphylactic reactions, facial swelling, angioneurotic edema) have been reported.
In individual medical publications, the development of hypercalciuria against the background of calcium supplement intake has been reported.
Rarely flatulence, constipation, diarrhea, nausea, vomiting, epigastric pain.
When taken in high doses (2000 mg/day with daily intake for several months) headache, increased fatigue, thirst, polyuria may be observed.
Contraindications
Hypersensitivity to the components of the combination, hypercalcemia, hypercalciuria, chronic renal failure, nephrourolithiasis, nephrocalcinosis, children under 3 years of age (depending on the used dosage form).
Use in Pregnancy and Lactation
Use during pregnancy and breastfeeding is possible as recommended by a doctor. Calcium penetrates into breast milk.
During pregnancy, the daily dose of calcium should not exceed 1500 mg. Hypercalcemia during pregnancy can cause disturbances in fetal development.
Use in Renal Impairment
Contraindicated in severe renal failure.
In patients with mild or moderate renal impairment, as well as with a history of urolithiasis, regular monitoring of urinary calcium excretion is required. In patients with renal impairment, the intake of calcium salts should be carried out under medical supervision. Monitoring of serum calcium and phosphate levels is necessary.
Pediatric Use
Use in children over 3 years of age is possible in appropriate dosage forms.
Geriatric Use
Use with caution in elderly patients to avoid the risk of exacerbation of chronic diseases.
Special Precautions
In patients with slight hypercalciuria (exceeding 300 mg or 7.5 mmol/day), with mild or moderate renal impairment, as well as with a history of urolithiasis, regular monitoring of urinary calcium excretion is required. If necessary, the dose of the used drug should be reduced or discontinued.
Patients prone to the formation of calculi in the urinary tract are recommended to increase fluid intake.
In patients with renal impairment, the intake of calcium salts should be carried out under medical supervision. Monitoring of serum calcium and phosphate levels is necessary.
When treating with calcium preparations, the intake of vitamin D or its derivatives in high doses should be avoided, unless there are special indications for this.
Drug Interactions
The combination Calcium carbonate+Calcium lactate gluconate may reduce the absorption of estramustine, etidronate and, possibly, other bisphosphonates, phenytoin, quinolones, oral tetracycline antibiotics, and fluoride preparations.
Concomitant administration of vitamin D and its derivatives increases the absorption of calcium. When prescribed in high doses together with vitamin D and its derivatives, calcium may reduce the effect of verapamil and, possibly, other calcium channel blockers.
With the simultaneous use of this combination and tetracycline antibiotics, the absorption of the latter may be impaired. For this reason, tetracyclines should be taken at least 2 hours before or 4-6 hours after oral administration of calcium preparations.
Thiazide diuretics reduce the urinary excretion of calcium, therefore, with their simultaneous use with this combination, regular monitoring of serum calcium concentration should be carried out, since there is a risk of developing hypercalcemia.
Systemic corticosteroids reduce the absorption of calcium.
When taking this combination in patients receiving cardiac glycosides, an increase in the toxicity of cardiac glycosides is possible due to the development of hypercalcemia. In such patients, regular monitoring of ECG and serum calcium levels is required.
When taking a bisphosphonate or sodium fluoride orally simultaneously, an interval of 3 hours before taking this combination must be observed, as the absorption of the bisphosphonate or sodium fluoride from the gastrointestinal tract may decrease.
The absorption of calcium from the gastrointestinal tract may decrease with the simultaneous intake of certain types of food containing oxalic acid (for example, spinach, rhubarb) or phytic acid (in all grains), due to the formation of insoluble complexes with calcium ions.
Patients should not take this combination 2 hours before or after eating food rich in oxalic or phytic acid.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Effervescent tablets 2.94 g+300 mg: 10 or 20 pcs.
Marketing Authorization Holder
Novartis Consumer Health S.A. (Switzerland)
Manufactured By
Famar France (France)
Dosage Form
| Calviv® | Effervescent tablets 2.94 g+300 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Effervescent tablets .
| 1 tab. | |
| Calcium lactate gluconate | 2.94 g |
| Calcium carbonate | 300 mg |
| Equivalent to Ca2+ content | 500 mg (12.5 mmol) |
10 pcs. – polypropylene jars (1) – cardboard packs.
20 pcs. – polypropylene jars (1) – cardboard packs.
Effervescent tablets 5.88 g+600 mg: 10 or 20 pcs.
Marketing Authorization Holder
Novartis Consumer Health S.A. (Switzerland)
Manufactured By
Famar France (France)
Dosage Form
| Calviv® | Effervescent tablets 5.88 g+600 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Effervescent tablets .
| 1 tab. | |
| Calcium lactate gluconate | 5.88 g |
| Calcium carbonate | 600 mg |
| Equivalent to Ca2+ content | 1 g (25 mmol) |
10 pcs. – polypropylene jars (1) – cardboard packs.
20 pcs. – polypropylene jars (1) – cardboard packs.
